163339-71-7

Basic information

• Product Name: methyl 2-bromo-2-(3,4-dichlorophenyl)acetate
• Synonyms: methyl 2-bromo-2-(3,4-dichlorophenyl)acetate
• CAS NO: 163339-71-7
• Molecular Weight: 297.963
• Mol File: 163339-71-7.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: methyl 2-bromo-2-(3,4-dichlorophenyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-bromo-2-(3,4-dichlorophenyl)acetate(163339-71-7)
• EPA Substance Registry System: methyl 2-bromo-2-(3,4-dichlorophenyl)acetate(163339-71-7)

Safety Data

• Hazardous Substances Data: 163339-71-7(Hazardous Substances Data)

Upstream product

• 6725-44-6 methyl 2-(3,4-dichlorophenyl)acetate 
• 3218-49-3 3,4-dichloro-benzeneacetonitrile 

Downstream Products

• 410074-74-7 (±)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane hydrochloride 
• 410074-74-7 Amitifadine hydrochloride 
• 344245-65-4 1-(3,4-dichlorophenyl)-1,2-cyclopropanedicarboxylic acid 
• 66504-44-7 (±)-1-(3,4 dichlorophenyl)-3-azabicyclo[3.1.0]-hexane-2,4-dione 
• 86215-36-3 (+/-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0.]hexane hydrochloride 
• 1186200-70-3 C₁₁H₁₀Cl₂O₃S 
• 877397-17-6 1-(3,4-dichlorophenyl)-1,2-cyclopropane-dicarboxylic acid dimethyl ester 
• 207404-79-3 [2-(4-{2-[2-(3,4-dichloro-phenyl)-4-(3,5-dimethyl-benzoyl)-piperazin-1-yl]-2-oxo-ethylamino}-piperidin-1-yl)-1-(1H-indol-3-ylmethyl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 207404-76-0 [(S)-2-(4-{2-[(R)-2-(3,4-Dichloro-phenyl)-4-(3,5-dimethyl-benzoyl)-piperazin-1-yl]-2-oxo-ethylamino}-piperidin-1-yl)-1-(4-hydroxy-benzyl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 207404-75-9 [(S)-1-Benzyl-2-(4-{2-[(R)-2-(3,4-dichloro-phenyl)-4-(3,5-dimethyl-benzoyl)-piperazin-1-yl]-2-oxo-ethylamino}-piperidin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 207404-82-8 [(R)-1-Benzyl-2-(4-{2-[(R)-2-(3,4-dichloro-phenyl)-4-(3,5-dimethyl-benzoyl)-piperazin-1-yl]-2-oxo-ethylamino}-piperidin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 207404-77-1 [(S)-2-(4-{2-[(R)-2-(3,4-Dichloro-phenyl)-4-(3,5-dimethyl-benzoyl)-piperazin-1-yl]-2-oxo-ethylamino}-piperidin-1-yl)-2-oxo-1-phenyl-ethyl]-carbamic acid tert-butyl ester 
• 207404-83-9 [(R)-2-(4-{2-[(R)-2-(3,4-Dichloro-phenyl)-4-(3,5-dimethyl-benzoyl)-piperazin-1-yl]-2-oxo-ethylamino}-piperidin-1-yl)-2-oxo-1-phenyl-ethyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

USE OF AMITIFADINE, (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN METHODS AND COMPOSITIONS WITH ENHANCED EFFICACY AND REDUCED METABOLIC SIDE EFFECTS AND TOXICITY FOR TREATMENT OF DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIO

The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azab

PROCESS FOR PRODUCTION OF THIOPHENE COMPOUND AND INTERMEDIATE THEREOF

To provide a novel process for producing a 2-aryl-3-hydroxy-4-substituted carbonyl thiophene compound or an intermediate thereof useful as an intermediate for production of medicines and agricultural chemicals. A 2-aryl acetate compound represented by the formula (1): wherein R1 is an aryl group or the like, R4 is a C1-3 alkyl group or the like, and X is a leaving group, is reacted with a thioacetic acid compound to form a thioacetyl compound (3), the thioacetyl compound (3) is reacted with a vinyl ketone compound to form a γ-ketosulfide compound (5), which is cyclized under basic conditions to form a dihydrothiophene compound (6), and the dihydrothiophene compound (6) is oxidized by using an oxidizing agent to produce a 2-aryl-3-hydroxy-4-substituted carbonyl thiophene compound (7).

NOVEL POLYMORPHS OF AZABICYCLOHEXANE

The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3, 4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.